Search results for "DM"

showing 10 items of 8932 documents

Alteration of loosely bound calcium in the guinea pig organ of Corti after treatment with diltiazem as calcium channel blocker

1997

After oral administration of the organic calcium channel blocker diltiazem to guinea pigs for 7 days, calcium ions were precipitated with potassium antimonate in the cochleae. The spatial distribution of the precipitates was studied by energy-filtering transmission electron microscopy and the amount of the ultrastructural reaction products formed was determined semiquantitatively by an image processing system. Compared with untreated control ears, the number of the formed precipitates was reduced drastically in the inner hair cells after diltiazem treatment. In addition, electron microscopic analysis revealed that the number of calcium precipitates attached at the basolateral membrane of th…

medicine.drug_classGuinea PigsAdministration Oralchemistry.chemical_elementCalcium channel blockerCalciumGuinea pigDiltiazemmedicineAnimalsDiltiazemOrgan of CortiLamina reticularisVoltage-dependent calcium channelbusiness.industryGeneral MedicineAnatomyCalcium Channel BlockersMicroscopy Electronmedicine.anatomical_structureOtorhinolaryngologychemistryOrgan of CortiBiophysicsUltrastructureCalciumCalcium Channelsbusinessmedicine.drugEuropean Archives of Oto-Rhino-Laryngology
researchProduct

Anti-inflammatory activity of two cucurbitacins isolated from Cayaponia tayuya roots.

2004

Fractionation of an anti-inflammatory extract from Cayaponia tayuya roots yielded two active compounds, identified as 23,24-dihydrocucurbitacin B (1) and cucurbitacin R (2). Both were evaluated for their anti-inflammatory activity on several experimental models of pain and inflammation. In addition, their cytotoxicity and effects on leukotriene B 4 (LTB 4 ) formation were evaluated in rat polymorphonuclear leukocytes. Both compounds showed activity in the following models: carrageenan-induced mouse paw oedema (1, 4 mg/kg p.o., 46% inhibition at 3 h), phospholipase A 2 -induced mouse paw oedema (2, 3 mg/kg i.p., 61% inhibition at 60 min), serotonin-induced mouse paw oedema (1 and 2, 0.5 mg/k…

medicine.drug_classLeukotriene B4Pharmaceutical ScienceAdministration OralPainPharmacologyAdministration CutaneousCarrageenanLeukotriene B4Plant RootsAnti-inflammatoryPhospholipases AAnalytical Chemistrychemistry.chemical_compoundMicePhospholipase A2Drug DiscoverymedicineLeukocytesAnimalsEdemaRats WistarPharmacologyPhospholipase AbiologyDose-Response Relationship DrugPlant ExtractsAntiglucocorticoidOrganic ChemistryAnti-Inflammatory Agents Non-SteroidalCucurbitacinsbiology.organism_classificationCayaponia tayuyaTriterpenesCarrageenanRatsCucurbitaceaePhospholipases A2Complementary and alternative medicinechemistryBiochemistryEicosanoidbiology.proteinMolecular MedicineTetradecanoylphorbol AcetateFemalePhytotherapyPlanta medica
researchProduct

Role of FODMAPs in Patients With Irritable Bowel Syndrome.

2015

Irritable bowel syndrome (IBS) is a condition characterized by abdominal pain, bloating, flatus, and altered bowel habits. The role of dietary components in inducing IBS symptoms is difficult to explore. To date, foods are not considered a cause but rather symptom-triggering factors. Particular interest has been given to the so-called FODMAPs (fermentable oligo-, di-, and monosaccharides and polyols). We aimed to summarize the evidence from the most common approaches to manage suspected food intolerance in IBS, with a particular interest in the role of FODMAPs and the effects of a low FODMAP diet. We reviewed literature, consulting PubMed and Medline by using the search terms FODMAP(s), fru…

medicine.medical_specialtyAbdominal painDiet therapyMedicine (miscellaneous)OligosaccharidesGastroenterologyIrritable Bowel Syndromechemistry.chemical_compoundBloatingSugar AlcoholsInternal medicineDietary CarbohydratesMedicineHumansIrritable bowel syndromechemistry.chemical_classificationNutrition and Dieteticsbusiness.industryMonosaccharidesAbdominal distensionmedicine.diseaseDietFood intoleranceIsomaltchemistryFermentationmedicine.symptombusinessFODMAPNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
researchProduct

Definitive Abutments Placed at Implant Insertion and Never Removed: Is It an Effective Approach? A Systematic Review and Meta-Analysis of Randomized …

2017

Purpose To assess whether repeated abutment disconnections and reconnections have any impact on peri-implant bone resorption and soft tissue healing. Materials and Methods Electronic and manual searches were conducted for English-language articles published up to March 2017 that identified a relation between repeated disconnections of implant abutments (PA group) and prosthetic or implant failures, complications, marginal bone loss (MBL), soft tissue healing, and esthetic evaluation (pink esthetic score [PES]) after at least 1 year of function compared with implants receiving a final abutment at the time of implant placement (DA group). Results Fourteen articles (535 patients with 994 impla…

medicine.medical_specialtyAbutmentDentistryDental Abutmentslaw.invention03 medical and health sciences0302 clinical medicineDental AbutmentsRandomized controlled triallaw0502 economics and businessmedicineHumansDental Restoration FailureBone ResorptionDental ImplantsWound Healingbusiness.industry05 social sciencesSoft tissueDental Implant-Abutment Design030206 dentistryBuccal administrationSurgeryDental Implant-Abutment DesignOtorhinolaryngologyMeta-analysis050211 marketingSurgeryImplantOral SurgerybusinessJournal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
researchProduct

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

2020

AbstractHemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The…

medicine.medical_specialtyAcetylgalactosamineInjections SubcutaneousLipoproteinsHemorrhage030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedHemophilia AHemophilia BSeverity of Illness IndexDisease courseFactor IX03 medical and health sciencesRoute of administrationLife Expectancy0302 clinical medicineAntibodies BispecificmedicineHumansRNA Small InterferingInfusions IntravenousIntensive care medicineFactor IXClotting factorClinical Trials as TopicFactor VIIICoagulantsbusiness.industryGenetic TherapyHematologyIntravenous InfusionsHistory 20th CenturyBlood Coagulation FactorsLaboratoriesbusiness030215 immunologymedicine.drugHämostaseologie
researchProduct

Topical application of the adenosine A2Areceptor agonist CGS-21680 prevents phorbol-induced epidermal hyperplasia and inflammation in mice

2014

The nucleoside adenosine is a known regulator of immunity and inflammation that mediates, at least in part, the anti-inflammatory effect of methotrexate, an immunosuppressive agent widely used to treat autoimmune inflammatory diseases. Adenosine A2A receptors play a key role in the inhibition of the inflammatory process besides promoting wound healing. Therefore, we aimed to determine the topical effect of a selective agonist, CGS-21680, on a murine model of skin hyperplasia with a marked inflammatory component. Pretreatment with either CGS-21680 (5 μg per site) or the reference agent dexamethasone (200 μg/site) prevented the epidermal hyperplasia and inflammatory response induced by topica…

medicine.medical_specialtyAdenosineAdenosine A2 Receptor AgonistsAdministration Topicalmedicine.medical_treatmentAnti-Inflammatory AgentsAdenosine A2A receptorInflammationDermatologyPharmacologyBiologySkin DiseasesBiochemistryDexamethasoneMicechemistry.chemical_compoundInternal medicinePhenethylaminesmedicineAnimalsMolecular BiologyDexamethasoneCell ProliferationPeroxidaseCGS-21680InflammationHyperplasiaAdenosineAdenosine receptorDisease Models AnimalEndocrinologyCytokinechemistryCytokinesTetradecanoylphorbol AcetateFemaleCollagenEpidermismedicine.symptomWound healingmedicine.drugExperimental Dermatology
researchProduct

Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review.

2018

Direct oral anticoagulants (DOACs) are indicated in the treatment and prevention of venous thromboembolism (VTE). However, the use of DOACs in unusual VTE, including cerebral venous thrombosis (CVT) and splanchnic venous thrombosis (SVT), and in patients with biological thrombophilia including minor thrombophilia (Factor V Leiden and prothrombin G20210A), major innate thrombophilia (protein C and S deficiency, and antithrombin) and major acquired thrombophilia (antiphospholipid syndrome [APS]), remains controversial due to the paucity of available data. There are some reports of DOACs use in the initial treatment or long-term maintenance of patients with either CVT or SVT, but their efficac…

medicine.medical_specialtyAdministration Oral030204 cardiovascular system & hematologyThrombophilialaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialAntiphospholipid syndromelawInternal medicinemedicineFactor V LeidenHumansThrombophilia030212 general & internal medicineVenous ThrombosisClinical Trials as Topicbusiness.industryAntithrombinAnticoagulantsHematologymedicine.diseaseAntiphospholipid Syndrome3. Good healthVenous thrombosisTreatment OutcomeOncologyProthrombin G20210AbusinessProtein Cmedicine.drugBlood reviews
researchProduct

Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: Rationale and design of the HoT-PE Trial

2016

SummaryPulmonary embolism (PE) is a potentially life-threatening acute cardiovascular syndrome. However, more than 95 % of patients are haemodynamically stable at presentation, and among them are patients at truly low risk who may qualify for immediate or early discharge. The Home Treatment of Pulmonary Embolism (HoT-PE) study is a prospective international multicentre single-arm phase 4 management (cohort) trial aiming to determine whether home treatment of acute lowrisk PE with the oral factor Xa inhibitor rivaroxaban is feasible, effective, and safe. Patients with confirmed PE, who have no right ventricular dysfunction or free floating thrombi in the right atrium or ventricle, are eligib…

medicine.medical_specialtyAdministration OralHome treatment; Management trial; Pulmonary embolism; Risk stratification; Rivaroxaban; HematologySelf Administration030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePatient satisfactionQuality of lifeRivaroxabanRecurrenceRisk FactorsInternal medicinemedicineHumansProspective Studies030212 general & internal medicineIntensive care medicineProspective cohort studyEarly dischargeRisk stratificationRivaroxabanbusiness.industryPulmonary embolismHome treatmentManagement trialHematologymedicine.diseaseHome Care ServicesComorbidityPatient DischargePulmonary embolismCohortQuality of LifebusinessFactor Xa Inhibitorsmedicine.drug
researchProduct

Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents

2005

More than 65 million Americans are currently obese. Type 2 diabetes mellitus, frequently seen in obese subjects, affects 17 million adults in the United States, with a continuous and alarmingly increasing rate. To prevent development of diabetes in those who are at high risk, it is recommended to optimize meal planning and enhance physical activity to make sustained weight reduction possible. In addition to lifestyle changes, various oral antidiabetic agents are available, with diverse mechanisms of action. Some target defective insulin secretion (sulphonylureas, benzoic acid derivatives) or glucose absorption (glycosidase inhibitors), whereas others target insulin resistance (metformin, th…

medicine.medical_specialtyAdministration OralType 2 diabetes.PharmacologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsMetabolic SyndromeHyperplasiabusiness.industryTroglitazoneType 2 Diabetes Mellitusmedicine.diseaseMetforminTreatment OutcomeEndocrinologyBlood VesselsMetabolic syndromebusinessDiabetic AngiopathiesDyslipidemiamedicine.drugCurrent Hypertension Reports
researchProduct

Management of oral Graft versus Host Disease with topical agents: a systematic review

2015

Background: Oral Graft-versus-Host Disease (oGvHD) is a common complication of haematopoietic stem cell transplantation. Choosing the right topical application to be used intra orally can be a challenge. Consequently, the aim of this work is to review the effectiveness and safety of topical agents currently used in the management of the inflammatory mucosal lesions encountered in oGVHD. Material and Methods: We carried out electronic searches of publications up to May 2015 of the databases Pubmed, National Library of Medicine’s Medline, Embase and the Cochrane Central Register of Controlled Clinical trials to identify potentially relevant studies (keywords: “oral”, “graft”, “versus”, “host”…

medicine.medical_specialtyAdministration TopicalGraft vs Host DiseaseOdontologíaReviewDisease03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineGlucocorticoidsGeneral Dentistrybusiness.industryMucosal lesions030206 dentistryMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryTransplantationGraft-versus-host diseaseOtorhinolaryngologyTopical agents030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryStem cellMouth DiseasesbusinessComplicationImmunosuppressive Agents
researchProduct